Insight Molecular Diagnostics Inc. (IMDX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Insight Molecular Diagnostics Inc. (IMDX) has a cash flow conversion efficiency ratio of 0.435x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-9.27 Million) by net assets ($-21.30 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see IMDX stock market capitalisation for the company's overall valuation and market capitalisation.
Insight Molecular Diagnostics Inc. - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Insight Molecular Diagnostics Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Insight Molecular Diagnostics Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Insight Molecular Diagnostics Inc. ranked by their cash flow conversion efficiency. Explore Insight Molecular Diagnostics Inc. (IMDX) cash flow quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
NeoPharm CO. LTD
KQ:092730
|
0.031x |
|
BINEX Co. Ltd
KQ:053030
|
0.019x |
|
TuHURA Biosciences Inc
NASDAQ:HURA
|
-0.467x |
|
Hoteles City Express S.A.B. de C.V
MX:HCITY
|
0.030x |
|
Komplett AS
OL:KOMPL
|
0.129x |
|
Kt Skylife
KO:053210
|
0.039x |
|
Media Nusantara Citra Tbk PT
JK:MNCN
|
0.008x |
|
Annehem Fastigheter AB
ST:ANNE-B
|
0.012x |
Annual Cash Flow Conversion Efficiency for Insight Molecular Diagnostics Inc. (2013–2025)
The table below shows the annual cash flow conversion efficiency of Insight Molecular Diagnostics Inc. from 2013 to 2025. View IMDX live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-31.46 Million | $-22.18 Million | 0.705x | -58.22% |
| 2024-12-31 | $-12.27 Million | $-20.71 Million | 1.688x | +248.08% |
| 2023-12-31 | $20.47 Million | $-23.32 Million | -1.140x | +0.98% |
| 2022-12-31 | $39.59 Million | $-45.57 Million | -1.151x | -108.83% |
| 2021-12-31 | $65.22 Million | $-35.94 Million | -0.551x | +28.97% |
| 2020-12-31 | $33.48 Million | $-25.98 Million | -0.776x | -21.37% |
| 2019-12-31 | $30.84 Million | $-19.71 Million | -0.639x | +81.21% |
| 2018-12-31 | $3.42 Million | $-11.65 Million | -3.403x | -11.95% |
| 2017-12-31 | $4.40 Million | $-13.38 Million | -3.040x | -298.57% |
| 2016-12-31 | $9.86 Million | $-7.52 Million | -0.763x | -87.88% |
| 2015-12-31 | $10.42 Million | $-4.23 Million | -0.406x | -137.46% |
| 2014-12-31 | $-1.07 Million | $-1.16 Million | 1.084x | +651.82% |
| 2013-12-31 | $3.62 Million | $-710.00K | -0.196x | -- |
About Insight Molecular Diagnostics Inc.
Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expre… Read more